Studies molecular causes and risks of kidney, immune and transplant-related diseases
Collects biological samples from adults with kidney, immune or transplant-related diseases to study them.
Key facts
- Who runs it
- University Hospital, Toulouse
- Where
- Toulouse, FranceSee the site
- Trial code
- Registry title
- Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
- Status
- Recruiting
- People taking part
- 5,000 people, planned
- Started
- 5 Sept 2022
- Expected to end
- 1 Sept 2032
- Type of study
- Observational
- Treatments tested
- Biological samples collection
- Record updated
- 19 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with kidney disease, or at risk of kidney disease, who are followed in the nephrology and organ transplantation department of Toulouse University Hospital in France.
- Age
- Over 18 years (the record lists 18 to 99 years)
- Sex
- Men and women
- Disease stage
- Kidney disease, or at risk of developing kidney disease
Main reasons for not taking part
- The person refuses to give consent
- The person or their family is unable to give consent
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Patients (> 18 year of age) with kidney disease or at risk to develop a kidney disease,
- Patients followed by a practitioner of the Department of Nephrology and Organ Transplantations of the University Hospital of Toulouse (France)
Who cannot take part
- consent deny
- inability of the patient or its family to give consent
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Where in France
- Rangueil University HospitalToulouse, FranceContact: Stanislas Faguer, MD, PhDTaking people
About the trial
What the trial wants to find out
Managing patients with renal failure requires an understanding of the molecular mechanisms that lead to its occurrence (i.e. upstream of the disease), its worsening and its persistence (i.e. downstream), while also specifying the risk of worsening renal failure (risk stratification, intolerance to the treatment or complications (infectious, metabolic, cardiovascular, cancer…). Nephrogene 2.0 aims to study these different components of kidney, immune and solid organ transplantation (SOT)-related diseases.
Treatments tested
- Biological samples collection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
- Plain-language title
- Studies molecular causes and risks of kidney, immune and transplant-related diseasesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05318196, who can take part
- Record updated
- 19 March 2026